Clinical Trial Update: Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery [Phase 1]

View source ↗

Summary

Phase 1 trial update of sapanisertib with ziv-aflibercept in patients with recurrent, metastatic, or unresectable solid tumors, including fibrolamellar carcinom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrolamellar Carcinoma
• Ovarian Carcinoma
• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• Sapanisertib (sapanisertib)
• Zaltrap (ramucirumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Malignant Solid Neoplasm, Fibrolamellar Carcinoma | Phase 1 | Status: COMPLETED | Results posted: 2025-10-20